At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
CRDF Cardiff Oncology, Inc.
Trading 01-27 14:23:34 EST
2.03
-0.91
-30.95%
High2.10Low1.85Vol9.54M
Open2.06D1 Closing2.94Amplitude8.50%
Mkt Cap136.74MTradable Cap133.43MTotal Shares67.36M
T/O18.68MT/O Rate14.52%Tradable Shares65.73M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

BUZZ-Cardiff Oncology plunges after top executives step down
Reuters  ·  01-27 21:02
BUZZ-Cardiff Oncology plunges after top executives step down
Cardiff Oncology Reports Positive Phase 2 Results for Onvansertib in First-Line RAS-Mutated mCRC
Reuters  ·  01:11
Cardiff Oncology Reports Positive Phase 2 Results for Onvansertib in First-Line RAS-Mutated mCRC
BUZZ-U.S. STOCKS ON THE MOVE-RTX, Kimberly-Clark, HCA Healthcare
Reuters  ·  01-27 22:06
BUZZ-U.S. STOCKS ON THE MOVE-RTX, Kimberly-Clark, HCA Healthcare
Cardiff Oncology announces CEO Erlander, CFO Levine have stepped down
TIPRANKS  ·  01-27 20:16
Cardiff Oncology announces CEO Erlander, CFO Levine have stepped down
Cardiff Oncology announces update from CRDF-004, Phase 2 trial of onvansertib
TIPRANKS  ·  01-27 20:10
Cardiff Oncology announces update from CRDF-004, Phase 2 trial of onvansertib
Cardiff Oncology Inc: Data Support Selection of 30 Mg Onvansertib Dose for Registrational Program in First-Line Ras-Mutated Mcr
THOMSON REUTERS  ·  01-27 20:05
Cardiff Oncology Inc: Data Support Selection of 30 Mg Onvansertib Dose for Registrational Program in First-Line Ras-Mutated Mcr
Cardiff Oncology Inc: Onvansertib Added to Folfiri/Bev First-Line Standard of Care Regimen Showed Dose-Dependent Improvement in Overall Response Rates
THOMSON REUTERS  ·  01-27 20:05
Cardiff Oncology Inc: Onvansertib Added to Folfiri/Bev First-Line Standard of Care Regimen Showed Dose-Dependent Improvement in Overall Response Rates
Cardiff Oncology Inc - Mark Erlander and James Levine Step Down From CEO and CFO Roles
THOMSON REUTERS  ·  01-27 20:00
Cardiff Oncology Inc - Mark Erlander and James Levine Step Down From CEO and CFO Roles
Cardiff Oncology Announces Executive Leadership Changes as It Transitions to Late-Stage Clinical Development
THOMSON REUTERS  ·  01-27 20:00
Cardiff Oncology Announces Executive Leadership Changes as It Transitions to Late-Stage Clinical Development
Cardiff Oncology Inc - Mani Mohindru Appointed Interim CEO of Cardiff Oncology
THOMSON REUTERS  ·  01-27 20:00
Cardiff Oncology Inc - Mani Mohindru Appointed Interim CEO of Cardiff Oncology
Cardiff Oncology Announces New Clinical Data on Onvansertib in Chronic Myelomonocytic Leukemia
Reuters  ·  2025-12-09
Cardiff Oncology Announces New Clinical Data on Onvansertib in Chronic Myelomonocytic Leukemia
Cardiff Oncology Announces Clinical Data From Investigator-Sponsored Trial With Onvansertib in Chronic Myelomonocytic Leukemia at Ash 2025
THOMSON REUTERS  ·  2025-12-09
Cardiff Oncology Announces Clinical Data From Investigator-Sponsored Trial With Onvansertib in Chronic Myelomonocytic Leukemia at Ash 2025
Cardiff Oncology to Present at Sidoti’s Year-End Virtual Investor Conference
Reuters  ·  2025-12-08
Cardiff Oncology to Present at Sidoti’s Year-End Virtual Investor Conference
Cardiff Oncology to Present at Piper Sandler Healthcare Conference
Reuters  ·  2025-11-24
Cardiff Oncology to Present at Piper Sandler Healthcare Conference
Analysts Offer Insights on Healthcare Companies: Nkarta (NKTX), BioLife Solutions (BLFS) and Cardiff Oncology (CRDF)
TIPRANKS  ·  2025-11-11
Analysts Offer Insights on Healthcare Companies: Nkarta (NKTX), BioLife Solutions (BLFS) and Cardiff Oncology (CRDF)
Analysts Are Bullish on These Healthcare Stocks: Myomo (MYO), Cardiff Oncology (CRDF)
TIPRANKS  ·  2025-11-10
Analysts Are Bullish on These Healthcare Stocks: Myomo (MYO), Cardiff Oncology (CRDF)
Cardiff Oncology posts smaller-than-expected Q3 loss
Reuters  ·  2025-11-07
Cardiff Oncology posts smaller-than-expected Q3 loss
Cardiff Oncology Q3 EPS $(0.17) Beats $(0.20) Estimate, Sales $120.000K Beat $112.500K Estimate
Benzinga  ·  2025-11-07
Cardiff Oncology Q3 EPS $(0.17) Beats $(0.20) Estimate, Sales $120.000K Beat $112.500K Estimate
Cardiff Oncology Inc expected to post a loss of 20 cents a share - Earnings Preview
Reuters  ·  2025-11-04
Cardiff Oncology Inc expected to post a loss of 20 cents a share - Earnings Preview
Cardiff Oncology Inc. to Participate in H.C. Wainwright Global Investment Conference with CEO Mark Erlander Presenting
Reuters  ·  2025-08-29
Cardiff Oncology Inc. to Participate in H.C. Wainwright Global Investment Conference with CEO Mark Erlander Presenting

Introduction

Company Name.
Cardiff Oncology, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
Issue price:
--